共 50 条
Vitamin D prophylaxis in persons with epilepsy?
被引:0
|作者:
Sourbron, Jo
[1
]
Auvin, Stephane
[2
,3
,4
]
Cabral-Lim, Leonor
[5
]
Devlin, Anita
[6
]
Dluglos, Dennis
[7
]
Hosny, Hassan
[8
]
Marson, Tony
[9
]
Meador, Kimford J.
[10
]
Patel, Archana A.
[11
]
Penell, Page B.
[12
]
Riney, Kate
[13
,14
]
Trinka, Eugen
[15
,16
]
Wiebe, Samuel
[17
]
Lagae, Lieven
[1
]
机构:
[1] Univ Hosp KU Leuven, Dept Dev & Regenerat, Sect Pediat Neurol, Leuven, Belgium
[2] Hop Robert Debre, Serv Neurol Pediat, AP HP, Paris, France
[3] Univ Paris, INSERM NeuroDiderot, Paris, France
[4] Inst Univ France IUF, Paris, France
[5] Univ Philippines Manila, Philippine Gen Hosp, Coll Med, Hlth Sci Ctr,Dept Neurosci, Manila, Philippines
[6] Newcastle Univ, Great North Childrens Hosp, Newcastle Upon Tyne, England
[7] Childrens Hosp Philadelphia, Philadelphia, PA USA
[8] Cairo Univ, Kasr Al Ainy Fac Med, Dept Neurol, Cairo, Egypt
[9] Univ Liverpool, Inst Translat Med, Liverpool, England
[10] Stanford Univ, Stanford Sch Med, Dept Neurol & Neurol Sci, Palo Alto, CA USA
[11] Boston Childrens Hosp, Dept Neurol, Div Epilepsy & Clin Neurophysiol, Boston, MA USA
[12] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[13] Univ Queensland, Sch Med, Brisbane, Qld, Australia
[14] Queensland Childrens Hosp, Neurosci Unit, Brisbane, Qld, Australia
[15] Ctr Cognit Neurosci, Salzburg, Austria
[16] Univ Hlth Sci, Dept Publ Hlth Hlth Serv Res & Hlth Technol Assess, Med Informat &Technol, Hall In Tirol, Austria
[17] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada
来源:
关键词:
bone health;
monitoring;
osteoporosis;
risk factors;
supplementation;
BONE-MINERAL DENSITY;
CHEMICALLY-INDUCED SEIZURES;
ANTIEPILEPTIC DRUGS;
D DEFICIENCY;
OSTEOPOROSIS PREVENTION;
CALCIUM SUPPLEMENTATION;
ALKALINE-PHOSPHATASE;
PREMENOPAUSAL WOMEN;
VALPROIC ACID;
FRACTURE RISK;
D O I:
10.1111/epi.18046
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Limited guidelines exist regarding osteoporosis prevention in the general population. Despite being a subject of controversy, the majority of research suggests that decreased vitamin D levels correlate with increased bone turnover, that is, an important risk factor for osteoporosis development. In most guidelines, daily vitamin D supplementation is recommended. In persons with epilepsy (PWE), the situation is more complex, as other factors can increase the chance of being vitamin D deficient. Currently, there are no internationally accepted guidelines regarding monitoring bone health in PWE. Our aim was to review the existing evidence in PWE on: (1) risk factors for vitamin D deficiency, (2) the identification of higher risk groups, and (3) the optimal ways to monitor bone health. Our narrative review shows that: (1) anti-seizure medication (ASM) use, especially enzyme-inducing ASM (EIASM) and valproic acid, is identified as an important risk factor for impaired bone health (e.g., increased risk for osteoporosis/fractures and/or vitamin D deficiency); (2) higher risk groups within the PWE population are present: intellectual or physical disability, institutionalized patients, puberty, early onset epilepsy and developmental epileptic encephalopathies, postmenopausal women, and use of multiple ASM/concomitant drugs (e.g. corticosteroids); and (3) a monitoring scheme can be suggested including laboratory tests, bone density measurements, managing of risk factors, and/or vitamin D supplementation. Overall, regular vitamin D measurement in PWE is a cost-effective and practical method for monitoring vitamin D deficiency, whereas in high-risk patients the combination of vitamin D measurement and bone densitometry is recommended. There is not enough evidence to advocate continuous vitamin D supplementation in all PWE. Children with epilepsy should receive the recommended daily intake of vitamin D for age and additional monitoring and supplementation if at higher risk of deficiency. There is a need for prospective trials exploring the potential benefit of vitamin D supplementation in PWE.
引用
收藏
页码:2567 / 2579
页数:13
相关论文